.png "Elizabeth Volkmann, MD, MS photo")
Associate Professor, Division of Rheumatology
University of California, Los Angeles
Los Angeles, California, United States
Dr. Volkmann is the Director of the UCLA Scleroderma Center and the Founder and Co-Director of the UCLA Connective Tissue Disease-Related Interstitial Lung Disease (CTD-ILD) Program. Board-certified in Internal Medicine and Rheumatology, she cares for patients with systemic sclerosis and CTD-ILD. She is an active clinical and translational researcher. Her research largely focuses on understanding the cause of systemic sclerosis, identifying clinical and biological factors that predict outcomes in patients with systemic sclerosis, and helping to discover new therapies for systemic sclerosis and interstitial lung disease. She strives to provide humanistic and compassionate care and seeks to empower her patients to improve their health through traditional, as well as holistic treatment modalities.
Sunday, October 26, 2025
8:00 AM – 9:00 AM Central Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Atyr Pharma: Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Horizon: Grant/Research Support (Ongoing); Kadmon: Grant/Research Support (Ongoing); Prometheus: Grant/Research Support (Ongoing)
Sponsoring Women and Underrepresented Minorities in Team Science and Clinical Practice
Sunday, October 26, 2025
10:00 AM – 11:30 AM Central Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Atyr Pharma: Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Horizon: Grant/Research Support (Ongoing); Kadmon: Grant/Research Support (Ongoing); Prometheus: Grant/Research Support (Ongoing)
Updates in Pulmonary Hypertension in Connective Tissue Diseases
Monday, October 27, 2025
8:30 AM – 9:30 AM Central Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Atyr Pharma: Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Horizon: Grant/Research Support (Ongoing); Kadmon: Grant/Research Support (Ongoing); Prometheus: Grant/Research Support (Ongoing)
The Many Faces of ILD in Rheumatic Diseases
Monday, October 27, 2025
1:00 PM – 2:00 PM Central Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Atyr Pharma: Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Horizon: Grant/Research Support (Ongoing); Kadmon: Grant/Research Support (Ongoing); Prometheus: Grant/Research Support (Ongoing)
Tuesday, October 28, 2025
8:30 AM – 10:00 AM Central Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Atyr Pharma: Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Horizon: Grant/Research Support (Ongoing); Kadmon: Grant/Research Support (Ongoing); Prometheus: Grant/Research Support (Ongoing)
Tuesday, October 28, 2025
9:30 AM – 10:00 AM Central Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Atyr Pharma: Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Horizon: Grant/Research Support (Ongoing); Kadmon: Grant/Research Support (Ongoing); Prometheus: Grant/Research Support (Ongoing)
Challenges and Solutions for Management of Raynaud's Phenomenon
Tuesday, October 28, 2025
10:30 AM – 11:30 AM Central Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Atyr Pharma: Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Horizon: Grant/Research Support (Ongoing); Kadmon: Grant/Research Support (Ongoing); Prometheus: Grant/Research Support (Ongoing)
Say Cheese: Oral Health in Scleroderma and Sjögren's Disease
Wednesday, October 29, 2025
8:00 AM – 9:00 AM Central Time
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Atyr Pharma: Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); Horizon: Grant/Research Support (Ongoing); Kadmon: Grant/Research Support (Ongoing); Prometheus: Grant/Research Support (Ongoing)
